53 shortly thereafter a member of the committee is recorded as expressing concern that the committee might be understood to have approved a survey undertaken by the aca concerning pharmacy performance.
132 nonetheless, i am not persuaded that their conduct resulted in the decision of the committee being an improper exercise of the power vested in the committee by s 52d(2) of the act.
the committee noted additional information on post-marketing surveillance study, media survey and consumer/market research, as well as the experience gained by pharmacists on screening and consulting patients on the suitability of orlistat for other [conditions] .